Biomaterials · 2022 · 70 citations · 35 references
MedicineOncologyPharmacologyDrug DeliveryMedical OncologyTargeted Drug DeliveryCancer NanomedicineHepatocellular CarcinomaHepatocellular Carcinoma PharmacotherapyInterventional OncologyTargeted Cancer TherapyTargeted TherapyActive Tumor TargetingEliminationHepatocellular Carcinoma ResectionHepatocellular Carcinoma TreatmentLiver Metastases TreatmentLiver Tumor TherapyTumor-targeted Drug Delivery
Transcatheter arterial chemoembolization (TACE) is widely used for the treatment of advanced hepatocellular carcinoma (HCC). However, the long-term hypoxic microenvironment caused by TACE seriously affects the therapeutic effect of TACE. HIF-2α plays a crucial role on the chronic hypoxia process, which might be an ideal target for TACE therapy. Herein, a multifunctional polyvinyl alcohol (PVA)/hyaluronic acid (HA)-based microsphere (PT/DOX-MS) co-loaded with doxorubicin (DOX) and PT-2385, an effective HIF-2α inhibitor, was developed for enhanced TACE treatment efficacy. In vitro and in vivo studies revealed that PT/DOX-MS had a superior ability to treat HCC by blocking the tumor cells in G2/M phase, prompting cell apoptosis, and inhibiting tumor angiogenesis. The antitumor mechanisms of PT/DOX-MS were possibly due to that the introduction of PT-2385 could effectively inhibit the expression level of HIF-2α in hypoxic HCC cells, thereby down-regulating the expression levels of Cyclin D1, VEGF and TGF-α. In addition, the combination of DOX and PT-2385 could jointly inhibit VEGF expression, which was another reason accounting for the combined anti-cancer effect of PT/DOX-MS. Overall, our study demonstrated that PT/DOX-MS is a promising embolic agent for enhanced HCC treatment via the combined effect of hypoxia microenvironment improvement, chemotherapy, and embolization.
35
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda et al. · Gut · 2019 · 723 citations · Full text
Medicine, Oncology, Pharmacotherapy +17
Molecular landmarks of tumor hypoxia across cancer types
Vinayak Bhandari, Christianne Hoey, Lydia Liu et al. · Nature Genetics · 2019 · 717 citations
Medicine, Cancer Biology, Oncology +16
Tim Meyer, Richard Fox, Yuk Ting et al. · The Lancet. Gastroenterology & hepatology · 2017 · 497 citations · Full text
Pharmacy, Oncology, Pharmacotherapy +11
Karen T. Brown, Mithat Gönen, Anne M. Covey et al. · Journal of Clinical Oncology · 2016 · 377 citations · Full text
YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression
Yulin Shi, Songqing Fan, Mengge Wu et al. · Nature Communications · 2019 · 375 citations · Full text